Lia Gore

10.9k total citations · 2 hit papers
202 papers, 6.1k citations indexed

About

Lia Gore is a scholar working on Public Health, Environmental and Occupational Health, Oncology and Molecular Biology. According to data from OpenAlex, Lia Gore has authored 202 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Public Health, Environmental and Occupational Health, 77 papers in Oncology and 69 papers in Molecular Biology. Recurrent topics in Lia Gore's work include Acute Lymphoblastic Leukemia research (79 papers), Childhood Cancer Survivors' Quality of Life (33 papers) and CAR-T cell therapy research (30 papers). Lia Gore is often cited by papers focused on Acute Lymphoblastic Leukemia research (79 papers), Childhood Cancer Survivors' Quality of Life (33 papers) and CAR-T cell therapy research (30 papers). Lia Gore collaborates with scholars based in United States, Canada and France. Lia Gore's co-authors include Laura Q.M. Chow, Cindy L. O’Bryant, Sabine Eckhardt, Roger B. Cohen, Stephen Leong, Gerhard Zugmaier, Patrick A. Brown, Nicholas K. Foreman, D. Ross Camidge and Jeffrey Knipstein and has published in prestigious journals such as Cell, JAMA and Journal of Clinical Oncology.

In The Last Decade

Lia Gore

192 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

2013 459 citations David T. Teachey, Susan R. Rheingold et al. Blood profile →
Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia

2021 207 citations Patrick A. Brown, Lingyun Ji et al. profile →

Peers

Countries citing papers authored by Lia Gore

Since Specialization

Citations

This map shows the geographic impact of Lia Gore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lia Gore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lia Gore more than expected).

Fields of papers citing papers by Lia Gore

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lia Gore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lia Gore. The network helps show where Lia Gore may publish in the future.

Co-authorship network of co-authors of Lia Gore

This figure shows the co-authorship network connecting the top 25 collaborators of Lia Gore. A scholar is included among the top collaborators of Lia Gore based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lia Gore. Lia Gore is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Long-term Safety and Clinical Activity in Patients with Conventional Chondrosarcoma 2025 ·Clinical Cancer Research ·William D. Tap, Gregory M. Coté, Howard A. Burris, Lia Gore, Anthony Elias, M. Beeram, Anthony P. Conley, Diego A. Gianolio, (unknown), (unknown), Jonathan C. Trent	1
2	Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia 2024 ·Haematologica ·(unknown), Lia Gore	4
3	Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse 2023 ·Journal of Clinical Oncology ·Laura Hogan, Patrick A. Brown, Lingyun Ji, Xinxin Xu, Meenakshi Devidas, Teena Bhatla, Michael J. Borowitz, Elizabeth A. Raetz, Andrew J. Carroll, Nyla A. Heerema, Gerhard Zugmaier, Elad Sharon, M. Brooke Bernhardt, Stephanie Terezakis, Lia Gore, James A. Whitlock, Stephen P. Hunger, Mignon L. Loh	33
4	Hypertension in Pediatric Acute Lymphoblastic Leukemia Patients: Prevalence, Impact, and Management Strategies 2022 ·SHILAP Revista de lepidopterología ·(unknown), Kelly W. Maloney, Lia Gore, (unknown)	5
5	A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in Low Risk (LR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs): A Report from Children's Oncology Group Study AALL1331 2021 ·Blood ·Patrick A. Brown, Lingyun Ji, Xinxin Xu, Meenakshi Devidas, Laura Hogan, Teena Bhatla, Michael J. Borowitz, Elizabeth A. Raetz, Lia Gore, James A. Whitlock, Stephen P. Hunger, Mignon L. Loh	7
6	Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia 2021 ·Leukemia Research ·Hetty E. Carraway, Yazeed Sawalha, Ivana Gojo, Min-Jung Lee, Sunmin Lee, Yusuke Tomita, Akira Yuno, (unknown), B. Douglas Smith, Keith W. Pratz, Mark J. Levis, Steven D. Gore, Nilanjan Ghosh, Amy E. DeZern, Amanda L. Blackford, Maria R. Baer, Lia Gore, Richard Piekarz, Jane B. Trepel, Judith E. Karp	10
7	A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331 2019 ·Blood ·Patrick A. Brown, Lingyun Ji, Xinxin Xu, Meenakshi Devidas, Laura Hogan, Michael J. Borowitz, Elizabeth A. Raetz, Gerhard Zugmaier, Elad Sharon, Lia Gore, James A. Whitlock, Michael A. Pulsipher, Stephen P. Hunger, Mignon L. Loh	51
8	Phase I trial of the mTOR inhibitor everolimus in combination with multi‐agent chemotherapy in relapsed childhood acute lymphoblastic leukemia 2018 ·Pediatric Blood & Cancer ·Andrew E. Place, Yana Pikman, Kristen E. Stevenson, Marian H. Harris, Melinda Pauly, Maria Luisa Sulis, Nobuko Hijiya, Lia Gore, Todd M. Cooper, Mignon L. Loh, Giovanni Roti, Donna Neuberg, Sarah K. Hunt, (unknown), Kimberly Stegmaier, Stephen E. Sallan, Lewis B. Silverman	43
9	Accelerating Drug Development in Pediatric Cancer: A Novel Phase I Study Design of Venetoclax in Relapsed/Refractory Malignancies 2018 ·Future Oncology ·Andrew E. Place, Kelly C. Goldsmith, Jean‐Pierre Bourquin, Mignon L. Loh, Lia Gore, Daniel A. Morgenstern, Yeshwant D. Sanzgiri, David Hoffman, Ying Zhou, Jeremy A. Ross, Betty Prine, Mohamad Shebley, (unknown), Thalia A. Farazi, Su Young Kim, Maria Verdugo, (unknown), C. Michel Zwaan, Josef Vormoor	39
10	Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Minimum Age Working Group 2017 ·Journal of Clinical Oncology ·Lia Gore, S. Percy Ivy, Frank M. Balis, Eric H. Rubin, Katherine A. Thornton, Martha Donoghue, Samantha Roberts, Suanna S. Bruinooge, Jennifer L. Ersek, Nancy Goodman, Caroline Schenkel, Gregory H. Reaman	50
11	Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high‐risk stratum of patients with newly diagnosed high‐risk B‐lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131 2017 ·Cancer ·Wanda L. Salzer, Michael J. Burke, Meenakshi Devidas, Si Chen, Lia Gore, Eric Larsen, Michael J. Borowitz, Brent L. Wood, Nyla A. Heerema, Andrew J. Carroll, Joanne M. Hilden, Mignon L. Loh, Elizabeth A. Raetz, Naomi Winick, William L. Carroll, Stephen P. Hunger	39
12	A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study 2016 ·Clinical Cancer Research ·Todd M. Cooper, (unknown), Elena Eckroth, Jemily Malvar, Richard Sposto, Paul S. Gaynon, Bill H. Chang, Lia Gore, Keith J. August, Jessica A. Pollard, Steven G. DuBois, Lewis B. Silverman, Javier Oesterheld, Guy Gammon, Daniel Magoon, Colleen Annesley, Patrick A. Brown	56
13	Phase I Study of Oral Rigosertib (ON 01910.Na), a Dual Inhibitor of the PI3K and Plk1 Pathways, in Adult Patients with Advanced Solid Malignancies 2014 ·Clinical Cancer Research ·Daniel W. Bowles, Jennifer R. Diamond, Elaine T. Lam, Colin D. Weekes, David P. Astling, Ryan T. Anderson, Stephen Leong, Lia Gore, Marileila Varella‐Garcia, Brian W. Vogler, Stephen B. Keysar, (unknown), Dara L. Aisner, Chen Ren, Aik Choon Tan, François Wilhelm, Manoj Maniar, Sabine Eckhardt, Wells A. Messersmith, Antonio Jimeno	54
14	Multicenter Phase I Trial of the Mitogen-Activated Protein Kinase 1/2 Inhibitor BAY 86-9766 in Patients with Advanced Cancer 2013 ·Clinical Cancer Research ·Colin D. Weekes, Daniel D. Von Hoff, Alex A. Adjei, (unknown), Sabine Eckhardt, Lia Gore, Karl D. Lewis, Glen J. Weiss, Ramesh K. Ramanathan, Grace K. Dy, Wen Wang, (unknown), Cory Iverson, Jeffrey N. Miner, Zancong Shen, Li‐Tain Yeh, Ronald L. Dubowy, Michael Jeffers, Prabhu Rajagopalan, Neil J. Clendeninn	46
15	Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy breakdown → 2013 ·Blood ·David T. Teachey, Susan R. Rheingold, Shannon L. Maude, Gerhard Zugmaier, David M. Barrett, Alix E. Seif, Kim E. Nichols, (unknown), Michael Kalos, Robert A. Berg, Julie C. Fitzgerald, Richard Aplenc, Lia Gore, Stephan A. Grupp	459
16	Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors 2010 ·Clinical Cancer Research ·Michael S. Gordon, Christopher J. Sweeney, David S. Mendelson, S. Gail Eckhardt, Abraham Anderson, Darrin M. Beaupre, Daniel Branstetter, Teresa L. Burgess, Angela Coxon, Hongjie Deng, Paula Kaplan‐Lefko, Ian M. Leitch, Kelly S. Oliner, Lucy Yan, Min Zhu, Lia Gore	133
17	Pharmacokinetically Guided Phase 1 Trial of the IGF-1 Receptor Antagonist RG1507 in Children with Recurrent or Refractory Solid Tumors 2010 ·Clinical Cancer Research ·(unknown), Cynthia E. Herzog, Tanya Trippett, Joseph F. Grippo, (unknown), Elizabeth Fox, Margaret E. Macy, (unknown), Patricia Whitcomb, Alberta Aikin, Gail S. Wright, Sergey Yurasov, Frank M. Balis, Lia Gore	41
18	Exploratory biomarkers in the HGF/SF:c-Met axis: preclinical and clinical results 2008 ·Cancer Research ·Angela Coxon, Karen Rex, Jan Sun, Jodi Moriguchi, (unknown), Mark Ma, Abraham Anderson, Yun Lan, Michael A. Gordon, Lia Gore, Christopher Sweeney, Lucy Yan, Darrin M. Beaupre, Kelly S. Oliner, Teresa L. Burgess	2
19	A phase 1 study of belinostat (PXD101) in combination with bortezomib in patients with advanced solid tumors and lymphoma 2007 ·Molecular Cancer Therapeutics ·Cindy L. O’Bryant, Stephen Leong, D. Ross Camidge, Lia Gore, Sami Diab, (unknown), Justin Call, Jennifer L. Spratlin, James A. Zwiebel, Sabine Eckhardt	3
20	A phase I study of R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist given weekly in patients with advanced solid tumors 2007 ·Molecular Cancer Therapeutics ·Stephen Leong, Lia Gore, Robert S. Benjamin, Terri Warren, S. Gail Eckhardt, D. Ross Camidge, (unknown), (unknown), Stanley Frankel, Razelle Kurzrock	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact